OLMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OLMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-28), Olema Pharmaceuticals's share price is $9.95. Olema Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.89. Hence, Olema Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Olema Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
Olema Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.34. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.89.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 13.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -69.10% per year.
During the past 6 years, Olema Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 13.30% per year. The lowest was -111.10% per year. And the median was -104.80% per year.
The historical data trend for Olema Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Olema Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Olema Pharmaceuticals Quarterly Data | |||||||||||||||||||
Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Olema Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Olema Pharmaceuticals's Price-to-Free-Cash-Flow falls into.
Olema Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 9.95 | / | -1.89 | |
= | N/A |
Olema Pharmaceuticals's Share Price of today is $9.95.
Olema Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Olema Pharmaceuticals (NAS:OLMA) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Olema Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Cyrus Harmon | director, officer: Chief Technology Officer | C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107 |
Paradigm Biocapital Advisors Lp | 10 percent owner | 767 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10017 |
G. Walmsley Graham | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Kovacs Shane William Charles | officer: Ch. Operating & Financial Off. | PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Naseem Zojwalla | officer: Chief Medical Officer | C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107 |
Sean Bohen | director, officer: President and CEO | C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107 |
David C. Myles | officer: Chief Development Officer | C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107 |
J. Scott Garland | director | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Senai Asefaw | 10 percent owner | 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017 |
Paradigm Biocapital International Fund Ltd. | 10 percent owner | C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008 |
Biotechnology Value Fund L P | 10 percent owner | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Paradigm Biocapital Advisors Gp Llc | 10 percent owner | 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017 |
Kinney Horn | officer: Chief Business Officer | C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107 |
Yi Larson | director | C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
From GuruFocus
By Marketwired • 08-02-2023
By Marketwired • 11-02-2023
By sperokesalga sperokesalga • 05-02-2023
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 08-01-2023
By Marketwired • 08-08-2023
By Marketwired • 07-05-2023
By GuruFocus Research • 09-15-2023
By sperokesalga sperokesalga • 03-02-2023
By GlobeNewswire • 10-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.